Research programme: TNF receptor antagonists - Fulcrum Pharmaceuticals

Drug Profile

Research programme: TNF receptor antagonists - Fulcrum Pharmaceuticals

Alternative Names: TNF receptor antagonists research programme - Fulcrum Pharmaceuticals

Latest Information Update: 07 Mar 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fulcrum Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Inflammation; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 22 Feb 2005 Preclinical trials in Inflammation in USA (PO)
  • 22 Feb 2005 Preclinical trials in Psoriasis in USA (PO)
  • 13 Jul 2004 Preclinical trials in Rheumatoid arthritis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top